SK25299A3 - Transdermal therapeutical approach involving a combination of active substances containing oestriol - Google Patents

Transdermal therapeutical approach involving a combination of active substances containing oestriol Download PDF

Info

Publication number
SK25299A3
SK25299A3 SK252-99A SK25299A SK25299A3 SK 25299 A3 SK25299 A3 SK 25299A3 SK 25299 A SK25299 A SK 25299A SK 25299 A3 SK25299 A3 SK 25299A3
Authority
SK
Slovakia
Prior art keywords
estriol
combination
transdermal therapeutic
oestriol
therapeutic system
Prior art date
Application number
SK252-99A
Other languages
English (en)
Slovak (sk)
Inventor
Kleinsorgen Reinhard Von
Kleinsorgen Britta Von
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of SK25299A3 publication Critical patent/SK25299A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
SK252-99A 1996-09-04 1997-08-13 Transdermal therapeutical approach involving a combination of active substances containing oestriol SK25299A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19635883A DE19635883A1 (de) 1996-09-04 1996-09-04 Transdermales therapeutisches System mit einer Östriol enthaltenden Wirkstoffkombination
PCT/EP1997/004392 WO1998009631A1 (fr) 1996-09-04 1997-08-13 Systeme therapeutique transdermique mettant en oeuvre une combinaison de matieres actives a teneur en ostriol

Publications (1)

Publication Number Publication Date
SK25299A3 true SK25299A3 (en) 2000-08-14

Family

ID=7804611

Family Applications (1)

Application Number Title Priority Date Filing Date
SK252-99A SK25299A3 (en) 1996-09-04 1997-08-13 Transdermal therapeutical approach involving a combination of active substances containing oestriol

Country Status (17)

Country Link
EP (1) EP0927036B9 (fr)
JP (1) JP2000517324A (fr)
KR (1) KR20010029451A (fr)
CN (1) CN1228702A (fr)
AT (1) ATE289818T1 (fr)
AU (1) AU729898B2 (fr)
CA (1) CA2261655A1 (fr)
CZ (1) CZ70099A3 (fr)
DE (2) DE19635883A1 (fr)
ES (1) ES2239362T3 (fr)
IL (1) IL128768A0 (fr)
NO (1) NO991047L (fr)
NZ (1) NZ334443A (fr)
PL (1) PL332035A1 (fr)
SK (1) SK25299A3 (fr)
WO (1) WO1998009631A1 (fr)
ZA (1) ZA977895B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100266670A1 (en) 2007-12-10 2010-10-21 Akira Yamamoto Transdermally absorptive preparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
HU215124B (hu) * 1991-02-26 1998-09-28 Norwich Eaton Pharmaceuticals, Inc. Eljárás csontritkulás (osteoporosis) kezelésére szolgáló ösztrogént és difoszfonátot tartalmazó, szinergetikus hatású gyógyszerkészítmények előállítására
CA2131822C (fr) * 1992-03-21 2002-12-17 Walter Elger Utilisation de l'oestriol pour traiter l'osteoporose climaterique
JPH0679002A (ja) * 1993-12-14 1994-03-22 Hisamitsu Pharmaceut Co Inc 経皮投与用パッチシステム
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide

Also Published As

Publication number Publication date
ATE289818T1 (de) 2005-03-15
EP0927036A1 (fr) 1999-07-07
ZA977895B (en) 1998-03-02
AU729898B2 (en) 2001-02-15
JP2000517324A (ja) 2000-12-26
KR20010029451A (ko) 2001-04-06
DE19635883A1 (de) 1998-03-05
ES2239362T3 (es) 2005-09-16
EP0927036B1 (fr) 2005-03-02
NO991047D0 (no) 1999-03-03
AU4015097A (en) 1998-03-26
CZ70099A3 (cs) 1999-07-14
CA2261655A1 (fr) 1998-03-12
NO991047L (no) 1999-03-03
CN1228702A (zh) 1999-09-15
PL332035A1 (en) 1999-08-16
EP0927036B9 (fr) 2005-08-10
IL128768A0 (en) 2000-01-31
NZ334443A (en) 1999-08-30
WO1998009631A1 (fr) 1998-03-12
DE59712215D1 (de) 2005-04-07

Similar Documents

Publication Publication Date Title
RU2139056C1 (ru) Гормональная заместительная терапия
US5422119A (en) Transdermal hormone replacement therapy
JP5184727B2 (ja) 女性への非経口アンドロゲンステロイドの投与
AU711179B2 (en) Cyclophasic hormonal regimen containing antiprogestin and progestin
RU2340345C2 (ru) Схема восполнения эстрогена
JP3314207B2 (ja) ホルモン製剤及び方法
TWI362932B (en) Pharmaceutical composition for transdermal delivery and uses thereof
JPH03502932A (ja) 避妊システム及び方法
US5286490A (en) Transdermal fluoride medication
SK25299A3 (en) Transdermal therapeutical approach involving a combination of active substances containing oestriol
AU692155B2 (en) Method and composition for treatment of osteoporosis
MXPA99001793A (en) Transdermal therapeutical approach involving a combination of active substances containing oestriol
CA2171460C (fr) Preparation pour therapie de substitution, renfermant au moins une progesterone et au moins un oestrogene
MACMASTER et al. Treatment of severe weight loss with methandrostenolone—a less virilizing anabolic agent
EP0675720A1 (fr) Therapie de substitution hormonale transcutanee multiphase
Mishell Jr The transdermal contraceptive system: Efficacy and safety
AU3662300A (en) Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding
MXPA01008772A (en) Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding